QuantaFlo PAD Advantages
When paired with one of our sensors, our QuantaFlo PAD test analyzes patient arterial blood flow using volume plethysmography. Waveforms are presented visually for users as sensors are connected to patient digits.
On-screen instructions guide users easily through the PAD testing process, and analysis from the application will notify users of any adjustments required to achieve the optimal signal quality.
Results with actionable insights are available in under 3 minutes.
Highly portable and easy to use – only a sensor and a single mobile device are required to perform a QuantaFlo PAD test
Sensors are compatible with a wider range of patients, including those with non-compressible, calcified arteries
Detects earliest stages of atherosclerosis and all stages of PAD, providing insight into disease progression and severity
Results are supported by
peer-reviewed research and publications
How Does QuantaFlo Work?
When blood flow is obstructed, turbulent fluctuations occur in blood volume in the extremities. QuantaFlo PAD uses an infrared sensor to measure these fluctuations in both early and later stages of PAD, including in patients with calcified vessels.
PAD Testing at the Point of Care
QuantaFlo PAD gives providers the opportunity to improve patient outcomes and lower operating costs by providing fast, accurate test results for peripheral arterial disease directly at the point of care in less than 3 minutes.
QuantaFlo PAD runs on Windows, Android, and iOS for tablets and mobile, and can be integrated with enterprise-level data management systems (EMRs). Combined with the high portability of our solution, this means less time in front of a device, and more time spent caring for patients.
A Solution for Early Detection
QuantaFlo is our flagship solution that allows providers to test for early signs of Peripheral Arterial Disease (PAD) in a clinical or home setting, in a matter of minutes, using any compatible device.
ABI measurement uses a cuff-based system to measure arterial pressure in the arms and at two locations in the ankle. These pressure values are used to calculate the ABI ratio.
While ABI is able to sufficiently detect advanced PAD, it typically is unable to detect PAD at pre-clinical disease levels and in patients with calcified vessels.
QuantaFlo accuracy has shown to be higher than cuff-based ABI when evaluated by ultrasound or angiography.
Generally, QuantaFlo can detect even the earliest blood flow volume changes and is less affected by calcified vessels as seen with the limitations of cuff-based ABI testing method.
No! QuantaFlo PAD is a stand-alone test that supports clinicians in the early diagnosis of PAD and does NOT require confirmation by cuff-based ABI.
For patients presenting with symptoms and/or with severe disease, providers may opt to order a duplex ultrasound to identify specific location(s) and severity of any plaque lesions to determine a treatment plan.
SemlerServices™
SemlerAnalytics
Empower clinical, operational, and financial decision-making process with our three-tiered packages.
Testimonial
Dr. Long is a retired vascular surgeon and serves as Semler Scientific’s in-house medical director.
His wealth of knowledge and experience have helped guide the development of our QuantaFlo solution into what it is today.